OTCMKTS:AZNCF AstraZeneca (AZNCF) Stock Forecast, Price & News $146.90 +1.45 (+1.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$146.90▼$147.2950-Day Range$137.50▼$153.1052-Week Range$104.50▼$153.10Volume1,739 shsAverage Volume3,548 shsMarket CapitalizationN/AP/E Ratio180.02Dividend Yield1.91%Price TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest AstraZeneca MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.18Based on 21 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.92 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for AstraZeneca. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverAstraZeneca has a short interest ratio ("days to cover") of 23.7, which indicates bearish sentiment.Change versus previous monthShort interest in AstraZeneca has recently decreased by 81.19%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend LeadershipAstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AZNCF. Previous Next 1.0 News and Social Media Coverage News SentimentAstraZeneca has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the -0.04 average news sentiment score of Health Technology companies.News Coverage This WeekMarketBeat has tracked 21 news articles for AstraZeneca this week, compared to 11 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by Institutions40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 180.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 137.05.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 180.02, which means that it is trading at a more expensive P/E ratio than the Health Technology sector average P/E ratio of about 16.25. Previous Next See Top Rated MarketRank™ Stocks Here About AstraZeneca (OTCMKTS:AZNCF) StockAstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.Read More Receive AZNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Stock News HeadlinesJune 1, 2023 | marketbeat.com20 Best Healthcare Dividend Stocks to Invest in (AZNCF)Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.June 6, 2023 | bloomberg.comAstraZeneca’s Japan Partner to Go Solo on Future Cancer DrugsJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 6, 2023 | reuters.comSanofi-AstraZeneca's preventive RSV therapy appears safe, says FDA staffJune 5, 2023 | msn.comLung cancer deaths cut in half with AstraZeneca pill, large trial findsJune 5, 2023 | marketwatch.comAstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in TrialJune 5, 2023 | lse.co.ukAstraZeneca and Daiichi Sankyo report progress in cancer drug trialsJune 5, 2023 | lse.co.ukAstraZeneca stops Andexxa trial early, Tagrisso reduces death riskJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 5, 2023 | marketwatch.comAstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria MetJune 5, 2023 | msn.comStocks Mixed, Week Ahead, OPEC Cuts, Palo Alto Networks Joins S&P 500, AstraZeneca Lung Cancer Trial - 5 Things To KnowJune 4, 2023 | msn.comAstraZeneca's Imfinzi shows positive response in gastric cancersJune 4, 2023 | msn.comAstraZeneca lung cancer drug halves death risk from disease, landmark study findsJune 4, 2023 | msn.comAstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patientsJune 4, 2023 | ft.comAstraZeneca defies geopolitics to bet on ChinaJune 2, 2023 | tmcnet.comAESOP Technology Announces Collaboration with AstraZeneca Taiwan on Medigator: Advancing Shared Decision-Making in Precision MedicineJune 2, 2023 | marketwatch.comAstraZeneca Says Imfinzi Data Shows Improved Response in Gastric CancersJune 2, 2023 | msn.comAstraZeneca announces new drug to treat lung and liver cancers now available in the UAEJune 1, 2023 | thetimes.co.ukAstraZeneca prostate cancer treatment wins US approvalJune 1, 2023 | msn.comPharma giant AstraZeneca to halt development of a treatment for Crohn's diseaseJune 1, 2023 | marketwatch.comAstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentJune 1, 2023 | marketwatch.comAstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development ProgramJune 1, 2023 | msn.comAstraZeneca gains US approval for prostate cancer combo treatmentMay 27, 2023 | msn.comAstraZeneca aids government in fight vs kidney diseaseMay 26, 2023 | finance.yahoo.comAstraZeneca PLC: Reaffirming BUY; strong product pipelineMay 26, 2023 | lse.co.ukTOP NEWS: AstraZeneca's Ultomiris wins another approval in JapanMay 26, 2023 | msn.comAstraZeneca announces good results from endometrial cancer trialSee More Headlines AZNCF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceuticals: Major Sub-IndustryN/A SectorHealth Technology Current SymbolOTCMKTS:AZNCF CUSIPN/A CIK901832 WebN/A Phone442037495000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio180.02 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesPascal SoriotChief Executive Officer & Executive DirectorPam P. ChengExecutive VP-Operations & Information TechnologyAradhana SarinChief Financial Officer & Executive DirectorMenelas NICOLAS PangalosEVP-Biopharmaceuticals Research & DevelopmentCindy L. HootsChief Digital & Information OfficerKey CompetitorsGenomma Lab InternacionalOTCMKTS:GNMLFMindset PharmaOTCMKTS:MSSTFCellaVision AB (publ)OTCMKTS:CLVSFMedigeneOTCMKTS:MDGEFOlympusOTCMKTS:OLYMYView All CompetitorsInstitutional OwnershipBoston Common Asset Management LLCBought 271,130 shares on 5/17/2023Ownership: 0.000%Vigilant Capital Management LLCSold 125 shares on 5/1/2023Ownership: 0.000%View All Institutional Transactions AZNCF Stock - Frequently Asked Questions Should I buy or sell AstraZeneca stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZNCF shares. View AZNCF analyst ratings or view top-rated stocks. How have AZNCF shares performed in 2023? AstraZeneca's stock was trading at $139.28 at the beginning of 2023. Since then, AZNCF shares have increased by 5.5% and is now trading at $146.90. View the best growth stocks for 2023 here. Are investors shorting AstraZeneca? AstraZeneca saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 502,800 shares, a decline of 9.5% from the April 15th total of 555,700 shares. Based on an average daily volume of 21,500 shares, the days-to-cover ratio is currently 23.4 days. View AstraZeneca's Short Interest. Is AstraZeneca a good dividend stock? AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable. What is AstraZeneca's stock symbol? AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF." Who are AstraZeneca's major shareholders? AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%) and Vigilant Capital Management LLC (0.00%). How do I buy shares of AstraZeneca? Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AstraZeneca's stock price today? One share of AZNCF stock can currently be purchased for approximately $146.90. How can I contact AstraZeneca? The company can be reached via phone at 442037495000. This page (OTCMKTS:AZNCF) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.